期刊文献+

1294例女性高危型人乳头瘤病毒基因分型结果回顾性分析 被引量:23

Retrospective analysis of high risk human papillomavirus genotypes infection among 1 294 women
下载PDF
导出
摘要 目的了解北京地区妇科门诊就诊女性高危型人乳头瘤病毒(HPV)的感染及其基因亚型分布情况,为该市今后防治人乳头瘤病毒感染和宫颈癌提供参考依据。方法回顾性分析2013年1月至2014年5月该院妇科门诊就诊的1 294例女性宫颈拭子的13种高危型HPV基因分型检测结果,比较不同基因型的流行病学特点。采用SPSS17.0对数据进行统计学分析。结果 1 294例妇科门诊就诊女性中,以58型、16型和52型HPV最为常见,检出率分别为10.5%、9.2%和8.2%。各年龄段就诊女性中,30~〈40岁的HPV感染率最高(39.9%),其次为40~〈50岁、大于或等于60岁,差异无统计学意义(P〉0.05)。结论该地区妇科门诊就诊女性高危型HPV感染率较高,应加强HPV筛查力度,为今后HPV相关疾病的防治提供基础依据。 Objective To understand the prevalence and sub‐genotypes distribution situation of high risk human papillomavirus (HPV) infection in the gynecological outpatient department in Beijing area in order to provide the reference basis for the prevention and treatment of HPV infection and cervical cancer .Methods The detection results of 13 kinds of high risk HPV genotypes among 1 294 women in the gynecological outpatient department of this hospital from January 2013 to May 2014 were performed the retro‐spective analysis for comparing the epidemiological characteristics of different HPV genotypes .The SPSS17 .0 software was adopted to perform the statistical analysis .Results Among 1 294 detected women ,HPV‐58 ,HPV‐16 and HPV‐52 were most common ,the detection rates were 10 .5% ,9 .2% and 8 .2% respectively .Among various age groups ,the 30 - 〈 40 years group had the highest HPV detection rate(39 .9% ) ,followed by the 40 -〈50 years group and the ≥ 60 years group ,but the difference among them had no statistically significance (P〉0 .05) .Conclusion The women going to the local outpatient department have the higher prevalence of high risk HPV infection .The intensity of HPV screening should be strengthened in order to provide the fundamental basis for the prevention and treatment of HPV related diseases .
出处 《国际检验医学杂志》 CAS 2015年第6期796-797,800,共3页 International Journal of Laboratory Medicine
关键词 人乳头瘤病毒 基因型 宫颈癌 human papilloma virus genotype cervical cancer
  • 相关文献

参考文献7

  • 1Ronco G,Segnan N. HPV testing for primary cervical cancerscreening[J]. Lancet, 2007 ,370(9601) : 1740-1742.
  • 2Liu SS,Chan KY. Leung RC, et al. Prevalence and risk factors ofHuman Papillomavirus (HPV) infection in southern Chinesewomen-a population-based study [J]. PLoS One,2011,6 ( 5 ):19244.
  • 3Ye J , Cheng X,Chen X,et al. Prevalence and risk profile of cervi-cal Human papillomavirus infection in Zhejiang Province, south-east China:a population-based study[J], Virol J. 2010,23(7) :66.
  • 4Sun ZR, Ji YH, Zhou WQ, et al. Characteristics of HPV preva-lence among women in Liaoning province,China[J]. Int J Gynae-col Obstet,2010,109(2) :105-109.
  • 5Xue Y,Zhang W,Chen M,et al. “U” shape of age-specific preva-lence of high-risk human papillomavirus infection in women atten-ding hospitals in Shanghai, China [ J]. Eur J Obstet Gynecol Re-prod Biol,2009,145(2) :214-218.
  • 6侯萌,李娜,朱广霞,崔绪琴,安瑞芳.妇科门诊患者宫颈人乳头瘤病毒的感染情况分析[J].西安交通大学学报(医学版),2013,34(2):229-232. 被引量:61
  • 7李静,屠铮,赵超,宋丹,王鹤,崔淑慧,乔友林,魏丽惠,JL Belinson.北京市社区妇女人乳头瘤病毒感染率及其对HPV和疫苗认知情况的调查分析[J].中国肿瘤,2008,17(3):168-172. 被引量:89

二级参考文献32

  • 1黄雅,冯玉昆,周卓君,马德莹,伍智慧,马四梅.昆明地区妇女宫颈HPV感染状况[J].昆明医学院学报,2007,28(02B):71-76. 被引量:15
  • 2Lee PW, Kwan Tr, Tam KF, et al. Beliefs about cervical cancer and human papillomavirus (HPV) and acceptability of HPV vaccination among Chinese women in Hong Kong [J]. Prey Med, 2007, 45(2-3):130-134.
  • 3Marlow LV, Waller J, Wardle J. Public awareness that HPV is a risk factor for cervical cancer [J]. Br J Cancer, 2007, 97(5) :691-694.
  • 4Kahn JA, Rosenthal SL, Hamann T, et al. Attitudes about human papillomavirus vaccine in young women [J]. Int J STD AIDS, 2003, 14(5):300-306.
  • 5Constantine NA, Jerman P. Acceptance of human papillomavirus vaccination among Californian parents of daughters: a representative statewide analysis [J]. J Adolesc Health, 2007, 40(2):108-115.
  • 6Hausdorf K, Newman B, Whlteman D, et al. HPV vaccination: what do Queesland parents think[J]. Australian and New Zealand Journal of Public Health,2007,31(3):255-289.
  • 7Harper DM, Franco EL, Wheeler CM, et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial[J]. Lancet, 2006, 367(9518): 1247-1255.
  • 8Jacob M, Bradley J, Barone MA. Human papillomavirus vaccines: what does the future hold for preventing cervical cancer in resource-poor settings through immunization programs?[J]. Sex Transm Dis, 2005, 32(10):635-640.
  • 9Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics[J]. CA Cancer J Clin, 2002, 55(2):74-108.
  • 10Sankaranarayana R. Overview of cervical cancer in the developing world. FIGO 6th Annual Report on the Results of Treatment in Gynecological Cancer [J]. Int J Gyneacol Obstet, 1995, (Suppl 1):S205-S2102.

共引文献148

同被引文献203

引证文献23

二级引证文献304

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部